Patients with plasma cell disorders are able to develop and sustain an antibody response to SARS-CoV-2 following asymptomatic infection and whilst on immunomodulatory therapy

Chan, W. Y.; Sanchez, E.; Chavda, S.; Lecat, C.; Ainley, L.; Xu, K.; Wisniowski, B.; Mahmood, S.; Papanikolaou, X.; Kyriakou, C.; Sive, J.; Wechalekar, A.; Popat, R.; Rabin, N.; Lee, L.; Nastouli, E.; Yong, K.

Chan, W. Y.; Sanchez, E.; Chavda, S.; Lecat, C.; Ainley, L.; Xu, K.; Wisniowski, B.; Mahmood, S.; Papanikolaou, X.; Kyriakou, C.; Sive, J.; Wechalekar, A.; Popat, R.; Rabin, N.; Lee, L.; Nastouli, E.; Yong, K..

British Journal of Haematology ; 193:20-21, 2021.

Article in English | Web of Science | ID: covidwho-1227394

Search on Google

XML

Collection: Databases of international organizations Database: Web of Science Language: English Journal: British Journal of Haematology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML

Collection: Databases of international organizations Database: Web of Science Language: English Journal: British Journal of Haematology Year: 2021 Document Type: Article